PRODUCTS / Medicines / SEARCH RESULTS

Medicines

  • CLINITRAT
    MACROGOL 3350
    POTASSIUM CHLORIDE
    SODIUM CHLORIDE
    SODIUM HYDROGEN CARBONATE
    FORM
    ΚΟΝΙΣ ΓΙΑ ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ
    CONTENT
    (6.563+175.4+89.3+23.3) mg/sachet ή stick
    PACKAGE
    BTx10 SACHETS x 6.9G, BTx10 STICKS x 6.9G, BTx20 SACHETS x 6.9G, BTx20 STICKS x 6.9G
    THERAPEUTIC CATEGORY
    Medicinal products for gastrointestinal system
  • NOPAR
    HOMATROPINE METHYLBROMIDE
    FORM
    ΠΟΣΙΜΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ
    CONTENT
    4 mg/ml
    PACKAGE
    FLx15ML
    THERAPEUTIC CATEGORY
    Medicinal products for gastrointestinal system
  • ZOLIDEN
    RANITIDINE HYDROCHLORIDE
    FORM
    ΑΝΑΒΡΑΖΟΝΤΑ ΔΙΣΚΙΑ
    CONTENT
    150 mg
    PACKAGE
    BTx10, BTx12
    THERAPEUTIC CATEGORY
    Medicinal products for gastrointestinal system
    FORM
    ΕΠΙΚΑΛΥΜΜΕΝΑ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΑ
    CONTENT
    150 mg
    PACKAGE
    BTx20
    THERAPEUTIC CATEGORY
    Medicinal products for gastrointestinal system
    FORM
    ΑΝΑΒΡΑΖΟΝΤΑ ΚΟΚΚΙΑ
    CONTENT
    300 mg
    PACKAGE
    BTx10
    THERAPEUTIC CATEGORY
    Medicinal products for gastrointestinal system

ALKACITRAT

ΑΝΑΒΡΑΖΟΝΤΑ ΔΙΣΚΙΑ 2 g

Therapeutic indications: Indigestion (slow digestion, bloating).
Posology and method of administration: Oral use.
Dosage: For adults and children over 15 years: 1 to 3 tablets daily.
Method of administration : The effervescent tablets are dissolved in half a glass of water. ALKACITRAT is taken before or after meals. The duration of treatment is limited to 7 days.
Contraindications : Hypersensitivity to the active substance or to any of the excipients listed
Special warnings and precautions for use : ALKACITRAT contains 16.66 mmol sodium (or 383.2 mg) per dose. Patients on a controlled sodium diet should be considered.
Interactions with other medicines and forms of interaction : The data available to date do not indicate the existence of clinically significant interactions.
Fertility, pregnancy and lactation : Avoid during pregnancy and lactation due to lack of clinical and experimental data.
Effects on ability to drive and use machines : ALKACITRAT does not appear to affect the ability to drive and use machines.
Unwanted actions : Allergic reactions (urticaria, angioedema and rash) have been reported.
Overdose : No cases of overdose have been reported.
Pharmacodynamic properties : Pharmacotherapeutic group: Digestive and metabolic products, ATC code: A16AA06. Betaine citrate is traditionally used to treat indigestion symptoms. This information is based solely on tradition and years of experience.
List of excipients : Mannitol, Citric acid anhydrous, Sodium bicarbonate, Raspberry flavor, Sodium saccharin, Sodium benzoate, Polyethylene glycol 6000, Starch pregelatinized.
Licence number : 89058 / 10.10.2017….

Active substance: BETAINE CITRATE
Content: 2 g
Form: ΑΝΑΒΡΑΖΟΝΤΑ ΔΙΣΚΙΑ
Package: BTx10 (1 TUBE x 10), BTx10 (5 STRIPES x 2), BTx20 (10 STRIPES x 2), BTx20 (2 TUBES x 10)
Do not exceed the recommended daily dose

PEPTONORM

ΔΙΣΚΙΑ 1000 mg

For the treatment of peptic ulcer
Tablets: 1000 mg/tab

Active substance: SUCRALFATE
Content: 1000 mg
Form: ΔΙΣΚΙΑ
Package: BTx30
Do not exceed the recommended daily dose

PEPTONORM

ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ 1000 mg/5ml

For the treatment of peptic ulcer.
Oral Suspension: 1000 mg/5ml

Active substance: SUCRALFATE
Content: 1000 mg/5ml
Form: ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ
Package: FLx150ML
Do not exceed the recommended daily dose

PEPTONORM

ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΣΕ ΣΥΣΚΕΥΑΣΙΑ ΜΙΑΣ ΔΟΣΗΣ 1000 mg/5ml

Για τη βραχυχρόνια (έως 8 εβδομάδες) θεραπεία του δωδεκαδακτυλικού έλκους, της χρόνιας γαστρίτιδας και της πεπτικής οισοφαγίτιδας

  • Δισκία 1000 mg/tab
  • Κοκκία για πόσιμο εναιώρημα 1000 mg/sachet
  • Πόσιμο εναιώρημα 1000 mg/5 ml
  • Εναιώρημα πόσιμο μιας δόσης 1000 mg/5 ml sachet
Active substance: SUCRALFATE
Content: 1000 mg/5ml
Form: ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΣΕ ΣΥΣΚΕΥΑΣΙΑ ΜΙΑΣ ΔΟΣΗΣ
Package: BTx20 SACHETS x 5ML, BTx30 SACHETS x 5ML
Do not exceed the recommended daily dose

PEPTONORM

ΚΟΚΚΙΑ ΓΙΑ ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΣΕ ΣΥΣΚΕΥΑΣΙΑ ΜΙΑΣ ΔΟΣΗΣ 1000 mg/φακελίσκο

For the treatment of peptic ulcer.
Granules Oral Suspension: 1000 mg/sachet
Suspension Single Dose: 1000 mg/5ml sachet

Active substance: SUCRALFATE
Content: 1000 mg/φακελίσκο
Form: ΚΟΚΚΙΑ ΓΙΑ ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΣΕ ΣΥΣΚΕΥΑΣΙΑ ΜΙΑΣ ΔΟΣΗΣ
Package: BTx20 SACHETS, BTx30 SACHETS
Do not exceed the recommended daily dose

RHEOSTOP R

ΔΙΣΚΙΑ ΔΙΑΣΠΕΙΡΟΜΕΝΑ ΣΤΟ ΣΤΟΜΑ 2 mg
Active substance: LOPERAMIDE HYDROCHLORIDE
Content: 2 mg
Form: ΔΙΣΚΙΑ ΔΙΑΣΠΕΙΡΟΜΕΝΑ ΣΤΟ ΣΤΟΜΑ
Package: BTx6
Do not exceed the recommended daily dose

ZOLIDEN

ΑΝΑΒΡΑΖΟΝΤΑ ΔΙΣΚΙΑ 75 mg

Medicines for ulcer treatment/Antagonist of H2 histamine receptors.
Effervescent Granules: 300 mg/sachet
Effervescent Tablets: 150 mg/tab

Active substance: RANITIDINE HYDROCHLORIDE
Content: 75 mg
Form: ΑΝΑΒΡΑΖΟΝΤΑ ΔΙΣΚΙΑ
Package: BTx12
Do not exceed the recommended daily dose

ZOLIDEN

ΕΠΙΚΑΛΥΜΜΕΝΑ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΑ 75 mg
Active substance: RANITIDINE HYDROCHLORIDE
Content: 75 mg
Form: ΕΠΙΚΑΛΥΜΜΕΝΑ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΑ
Package: BTx10, BTx20
Do not exceed the recommended daily dose